The changing landscape of drug-coated technology in peripheral arterial disease
How has drug-coated technology changed the treatment of peripheral arterial disease, and what questions remain?
Drug-coated technologies have reshaped the treatment landscape in peripheral artery disease (PAD), but questions remain about the evidence supporting their use, their place in clinical practice and their long-term value.
The Essentials on DCBs explores the evidence behind these technologies, from clinical trials and treatment strategies to economic considerations and future directions, highlighting how they are evolving and what remains to be addressed.
EDITORIAL
From mechanics to biology
Setting the scene for the evolution of drug-coated technologies
Prakash Krishnan and David D. Song explore how drug-coated technologies are reshaping peripheral interventions, introducing the clinical, strategic and economic questions that underpin this evolving field.
CLINICAL TRIALS
From success to controversy
From landmark trials to emerging technologies
Eric Secemsky and Maxime Lebaz-Dubosq examine the evidence for DCBs and DESs, from the paclitaxel safety controversy to emerging sirolimus-based technologies and new approaches to below-the-knee disease.
CLINICAL ALGORITHMS
From evidence to decisions
Translating evidence into clinical decisions
Sabine Steiner and Koen Deloose discuss treatment strategies for femoropopliteal disease and in-stent restenosis, examining the role of DCBs, DESs and vessel preparation alongside persistent clinical challenges.
ECONOMIC CONSIDERATIONS
What is the true value?
Balancing costs, outcomes and long-term value
Jos C. Van Den Berg assesses the cost-effectiveness of DCBs and DESs, highlighting the role of clinical outcomes, healthcare costs and reimbursement policies in determining their economic value.
EDITORS' CONCLUSION
From long-term durability to patient-centered outcomes
From vessel patency to meaningful clinical benefit
Prakash Krishnan and David D. Song reflect on the evolving role of drug-coated technologies, highlighting the importance of translating improved vessel patency into meaningful, lasting clinical benefits for patients.
This special report is available thanks to the support of iVascular.
PVI online develops independent educational programmes.
